Medical workers from KinMed Diagnostics (Hefei) collect samples for nucleic acid testing in East China's Anhui province. [Photo/WeChat account: hefeigaoxinfabu]

KinMed Diagnostics (Hefei) has provided nucleic acid tests to more than 700,000 residents in East China's Anhui province as of 12 am on May 19, according to the company.

The medical company responded quickly when Anhui reported new COVID-19 cases on May 13 and has become one of the main players in the local COVID-19 testing efforts.

The company has sent a 150-man service team to the frontlines as well as increased its laboratory production capacity by eight times to aid epidemic control measures in the province.

Shen Menglai, vice general manager of KinMed Diagnostics (Hefei), said that the company is experienced in dealing with such urgent needs for COVID-19 testing.

Last year, KinMed Diagnostics (Hefei) was awarded a provincial honor for its contributions to the fight against COVID-19. The company performed over 3 million COVID-19 tests in 15 cities in Anhui during the outbreak.

Established in 2007 in the Hefei National High-tech Industry Development Zone, KinMed Diagnostics (Hefei) is a national high-tech company engaged in medical examination and a leading third-party medical laboratory in Anhui.